Navigation Links
A*STAR scientists' groundbreaking discovery of nucleus structure crucial to understanding diseases
Date:2/8/2013

1. Scientists from Singapore and Germany have identified that the proteins lamin A (Lmna) and lamin B receptor (Lbr) are essential for holding silent genes in their correct position at the edge of the nucleus, in the form of heterochromatin . A deviation from their normal position will cause the genes to malfunction, leading to heart failure, vascular disease and muscle wasting.

2. For hundreds of years before this discovery, scientists were puzzled by why heterochromatin clustered at the edge of the nucleus and how it was relevant to normal cell function. This recent discovery will enable scientists to gain a better understanding of the diseases of the heart and muscles, and find cures for them in the future.

3. The findings by Audrey Wang and Colin Stewart of A*STAR's Institute of Medical Biology and Irina Solovei, Boris Joffe and Heinrich Leonhardt of the Ludwig Maximillian University in Munich, Germany, were recently published in the prestigious journal Cell .

4. The nucleus the brain of the cell carries all the information, in the form of chromatin necessary to help a cell grow, thrive, and reproduce, in the form of DNA packed into chromatin. Hence, understanding how chromatin is organised in the nucleus is important to understanding disease and normal processes such as ageing. The scientists showed that the two proteins lamin A and lamin B receptor are important to the organisation of chromatin in the nucleus. Using mouse models, they demonstrated that in the absence of the two proteins, heterochromatin collapsed into the nuclear centre. This disrupted gene expression and affected skeletal muscle development, resulting in muscle failure (Annex A).

5. Professor Stewart, Research and Assistant Director of IMB, said, "These findings will provide new insights into how diseases arise and may help explain how mutations in lamin proteins result in a variety of different syndromes. In particular, we are extending these findings to explore how changes in chromatin position may contribute to heart failure. Moving forward, we will collaborate with cardiologists and vascular clinicians at SGH and NUHS to translate these findings to benefit patients."

6. Professor Birgitte Lane, Executive Director of IMB, said, "I would like to congratulate Colin and the team for this important piece of research. It brings us a step closer to understanding the nucleus and to developing new treatments for common diseases. It could be particularly relevant for Singapore, as we, like other developed nations, are facing an ageing population, and heart failure, vascular disease and muscle wasting all increase with age."


'/>"/>

Contact: Ong Siok Ming
ong_siok_ming@a-star.edu.sg
656-826-6254
Agency for Science, Technology and Research (A*STAR), Singapore
Source:Eurekalert  

Related biology news :

1. A*STAR scientists solve century-old mystery by finding stable haploid strains of Candida albicans
2. A*STAR scientists discover potential drug for deadly brain cancer
3. Breakthroughs in Chikungunya research from A*STAR spell new hope for better treatment and protection
4. Scientists identify genetic mechanism that contributed to Irish Famine
5. Scientists turn toxic by-product into biofuel booster
6. Scientists find a key element of lupus, suggesting better drug targets
7. Scientists notch a win in war against antibiotic-resistant bacteria
8. Plant scientists at CSHL demonstrate new means of boosting maize yields
9. Listening to cells: Scientists probe human cells with high-frequency sound
10. Joslin scientists find first human iPSC from patients with maturity onset diabetes of the young
11. Scientists uncover previously unknown mechanism of memory formation
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A*STAR scientists' groundbreaking discovery of nucleus structure crucial to understanding diseases
(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
(Date:2/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... the LEERINK Partners 6th Annual Global Healthcare Conference at ... 15, 2017 at 10 a.m. Eastern Time. ... accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will be ... Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, Inc. ... immuno-oncology company specializing in the development of innovative ... treatment of cancer and metastatic disease, announced today ... GMP manufacturing of a second clinical lot of ... folate receptor alpha. The manufactured vaccine product will ...
Breaking Biology News(10 mins):
(Date:2/20/2017)... , Feb. 20, 2017  Atrius Health and ... entered into an agreement to develop a cloud ... By providing a holistic view of the multiple ... Watson Cognitive Insights could be designed to support ... Health is an innovative nonprofit healthcare organization with ...
(Date:2/18/2017)... Feb 17, 2017 Research and Markets has ... Report" report to their offering. ... The report provides separate comprehensive analytics for ... , and Rest of World. Annual estimates and forecasts are provided ... is provided for these markets. Market data and analytics are derived ...
(Date:2/17/2017)...  Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today presented ... drug candidates, PTG-100 and PTG-200, at the 12 ... Colitis Organization (ECCO).  The ECCO congress is being ... from February 15 – 18, 2017. ... drug candidates PTG-100 and PTG-200. PTG-100, a potential ...
(Date:2/16/2017)... , Feb. 16, 2017  MDNA Life Sciences ... development of liquid biopsy tests based on the ... an exclusive license agreement with its first international ... liquid biopsy test for prostate cancer, the Prostate ... . This is the first overseas appointment ...
Breaking Biology Technology: